A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 412 participants.

Also called NCT03985293

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 412 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03985293
  • EudraCT 2019-000218-12
Other papers using this trial's data
  • Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial JAMA network open, 2023-05-01 DOI, PubMed 37213102, PMC10203889 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Hungary, Poland, Slovakia, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03985293. Randomized; quadruple masking; primary purpose treatment. Start 2019-10-15 (actual); primary completion 2021-06-08 (actual). Results posted on 2022-06-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
PF-06882961
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct03985293
Content hash
6192885beb9ff197beda1891542a79bc22a94fcf05eb0527313d33780b0fb4b8